What is your approach to determining fitness for patients to undergo CAR-T therapy for relapsed/refractory multiple myeloma, and any absolute perceived contraindications for CAR-T?

This is a great question to which the only truly correct answer is, "It depends." Not just on the patient & disease biology, of course, but also the year in which the question is answered. For example, right now there are patients for whom commercial cilta-cel or ide-cel are not appropriate because ...